Semin Thromb Hemost 2014; 40(07): 790-802
DOI: 10.1055/s-0034-1384636
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Emerging Therapies for Hemophilia: A New Era of Care and the Role of the Interdisciplinary Team

Michelle Witkop
1  Northern Regional Bleeding Disorders Center, Traverse City, Michigan
Susan Cutter
2  Penn Comprehensive Hemophilia and Thrombosis Program, University of Pennsylvania, Philadelphia, Pennsylvania
Joann Deutsche
3  Oregon Hemophilia Center, Oregon Health and Science Center, Portland, Oregon
Maria Santaella
4  Miami Hemophilia Treatment Center, University of Miami Miller School of Medicine, Miami, Florida
Robin Chapman
5  Children's Healthcare of Atlanta, Atlanta, Georgia
Jennifer Lafranco
6  Clinical Programs, Mary M. Gooley Hemophilia Center, Rochester General, Rochester, New York
Angela Lambing
7  Henry Ford Hospital, Hemophilia Treatment Center, Detroit, Michigan
› Institutsangaben
Weitere Informationen


21. August 2014 (online)


The introduction of new hemophilia management therapies, targeting extended half-lives through bioengineering, ushers in an era of potential promise and increasing complexity, more so for those with hemophilia B than hemophilia A. Questions arise for patients, caregivers, and hemophilia treatment center (HTC) staff about how to assess and incorporate novel therapies and how to determine whether new therapies offer a distinct advantage over established treatment routines. Nurses and other interdisciplinary HTC staff are well positioned to assess, educate, and support patients and families in navigating this rapidly changing landscape. To support these challenging efforts, this review offers a perspective on issues affecting therapeutic transitions and provides tools to foster ongoing adherence.